Avacta Group (LON:AVCT) Hits New 52-Week Low – Time to Sell?

Shares of Avacta Group Plc (LON:AVCT) hit a new 52-week low during trading on Tuesday . The company traded as low as GBX 39.25 ($0.50) and last traded at GBX 39.37 ($0.50), with a volume of 2737993 shares trading hands. The stock had previously closed at GBX 41.60 ($0.53).

Avacta Group Trading Down 3.0 %

The stock has a market cap of £155.76 million, a price-to-earnings ratio of -5.28 and a beta of 1.12. The company has a quick ratio of 4.96, a current ratio of 1.29 and a debt-to-equity ratio of 52.53. The business’s 50 day simple moving average is GBX 48.31 and its 200 day simple moving average is GBX 54.92.

Avacta Group Company Profile

Avacta Therapeutics is a clinical stage biopharmaceutical company challenging current drug delivery methods to expand the utility of highly potent cancer therapeutics.
The Company benefits from a world class research and development facility, team of exceptionally talented scientists and a highly experienced management team with members located in both the London headquarters and the US.

Our proprietary pre|CISION® platform masks toxic warheads by binding them to a short, engineered peptide that is cleavable only by the tumor-specific protease, fibroblast activation protein (FAP).